Roivant Sciences Ltd (NASDAQ: ROIV) is a biopharmaceutical company that develops drug candidates across multiple therapeutic areas through a portfolio of subsidiary companies. The company does not yet generate meaningful product revenue; it funds operations through capital raises and partnership arrangements while advancing clinical-stage programs. Its pipeline is organized around an anti-FcRn franchise targeting endocrine, neurological, rheumatology, and dermatology diseases, alongside programs including brepocitinib and mosliciguat. Program-specific R&D costs totaled $428.9 million for the fiscal year ended March 31, 2026, up from $327.8 million in FY2025 and $249.2 million in FY2024. The anti-FcRn franchise accounted for the largest share of those costs, with endocrine ($90.4M), neurological ($82.5M), and rheumatology ($48.8M) as the three largest individual line items in FY2026. Roivant also holds an investment in Datavant, a health data company. The company is incorporated outside the United States and files as a foreign private issuer on the Nasdaq Global Select Market.

Revenue model

Roivant is a pre-commercial or early-commercial stage biopharmaceutical company. The filing excerpts do not describe product sales revenue as a material income source. Operations are funded through equity capital and, where disclosed, licensing or partnership arrangements. The company incurs substantial R&D expenditures, with total program-specific costs of $428.9 million in FY2026.

Products and services

Anti-FcRn franchise programs targeting endocrine diseases, neurological diseases, rheumatology diseases, and dermatology diseases; brepocitinib (a JAK/TYK2 inhibitor in clinical development); mosliciguat (in clinical development); and other development and discovery programs. The batoclimab program within the anti-FcRn franchise was discontinued, incurring $39.0 million in contractual costs in FY2026. Roivant also uses AI tools in drug discovery activities including target identification and compound screening.

Customers and end markets

The filing excerpts do not identify commercial customers or product revenue end markets. Clinical programs target patients with endocrine, neurological, rheumatological, and dermatological diseases. Regulatory submissions reference the FDA (United States), EMA (European Union), and MHRA (United Kingdom) as approval bodies.

Value-chain role

Roivant occupies the drug development role in the pharmaceutical value chain: it licenses or originates drug candidates, funds and oversees clinical trials through contract research organizations (CROs), and relies on contract manufacturing organizations (CMOs) for manufacturing. It does not operate its own manufacturing facilities as described in the filing excerpts.

Geographic exposure

Roivant is incorporated outside the United States and lists on the Nasdaq Global Select Market. Clinical and regulatory activities span the United States (FDA), European Union (EMA), and United Kingdom (MHRA), including compliance with EU and UK pediatric investigation plan requirements and UK orphan drug designation under the Windsor Framework effective January 1, 2025.

Source: SEC 10-K, filed 2026-05-20

Industry: Pharmaceutical Preparations Peers: Kiniksa Pharmaceuticals International PLC